INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1

CUSIP: 45845PAB4

Q4 2019 13F Holders as of 31 Dec 2019

Type / Class
Debt / NOTE 2.000% 5/1
Market price (% of par)
132.68%
Total 13F principal
$195,783,000
Principal change
-$6,624,000
Total reported market value
$261,969,568
Number of holders
30
Value change
+$2,145,178
Number of buys
9
Number of sells
16

Quarterly Holders Quick Answers

What is CUSIP 45845PAB4?
CUSIP 45845PAB4 identifies 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 as of Q4 2019

As of 31 Dec 2019, INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 was held by 30 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $195,783,000 in principal (par value) of the bond. The largest 10 bondholders included FRANKLIN RESOURCES INC, Linden Advisors LP, CITADEL ADVISORS LLC, FARALLON CAPITAL MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, SSI INVESTMENT MANAGEMENT LLC, CNH PARTNERS LLC, FMR LLC, and BARCLAYS PLC. This page lists 30 institutional bondholders reporting positions for the Q4 2019 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.